通化金马(000766) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥315,750,993.99, representing a decrease of 1.34% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥4,773,724.67, down 3.27% year-on-year, while the net profit excluding non-recurring items increased by 11.24% to ¥3,132,788.39[3]. - Basic earnings per share for Q3 2023 were ¥0.0049, a decrease of 3.92% year-on-year, while diluted earnings per share remained the same[3]. - Total operating revenue for the period reached CNY 1,044,242,077.32, an increase of 3.3% compared to CNY 1,013,753,250.35 in the previous period[14]. - Net profit for the period was CNY 14,851,915.32, compared to CNY 11,726,341.24 in the previous period, representing an increase of 26.5%[15]. - Earnings per share (EPS) for the period was CNY 0.0161, up from CNY 0.0129 in the previous period[16]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,466,267,721.29, a decrease of 4.67% from the end of the previous year[3]. - The company's total current assets decreased from 1,238,370,787.12 to 1,049,016,294.36, a decline of approximately 15.3%[12]. - Cash and cash equivalents decreased from 336,821,630.18 to 181,006,983.27, representing a drop of about 46.3%[11]. - The total assets of the company decreased from 4,685,114,987.39 to 4,466,267,721.29, a reduction of approximately 4.7%[12]. - The company's total liabilities increased from 671,861,996.48 to 511,997,301.67, indicating a decrease of about 24.3%[12]. - The total liabilities decreased to CNY 2,148,434,563.34 from CNY 2,316,613,744.76, a reduction of 7.2%[15]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥85,035,967.09, reflecting a decline of 4.11% compared to the same period last year[3]. - Cash flow from operating activities totaled CNY 1,052,761,627.96, a decrease from CNY 1,074,408,967.19 in the previous period[17]. - The net cash flow from operating activities was $85,035,967.09, a decrease from $88,676,122.92 in the previous period, reflecting a decline of approximately 1.85%[18]. - The net cash flow from investing activities was $83,292,448.53, a significant improvement compared to a negative cash flow of -$15,353,252.35 in the previous period[18]. - Cash inflow from financing activities totaled $130,000,000.00, down from $1,607,000,000.00 in the previous period, indicating a decrease of approximately 91.88%[18]. - The total cash outflow from financing activities was $355,612,747.34, compared to $1,708,327,368.30 in the previous period, showing a reduction of about 79.16%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 66,592, with the largest shareholder holding 19.66% of shares[7]. - The number of shares held by the top ten shareholders includes 190,000,000 shares from the largest shareholder, indicating a concentrated ownership structure[7]. - The company has pledged shares totaling 150,000,000, indicating potential liquidity concerns among major shareholders[7]. Research and Development - The company is closely monitoring the Phase III clinical trial results of its new drug, which has recently unblinded[10]. - Research and development expenses increased to CNY 29,740,704.07 from CNY 24,238,112.30, marking a rise of 22.8%[14]. Other Financial Metrics - The weighted average return on equity was 0.20%, a slight decrease of 0.01% compared to the previous year[3]. - The company reported a significant increase in long-term deferred expenses by 78.35% due to workshop renovation costs[5]. - Investment income for the year-to-date increased by 117.93% compared to the same period last year, indicating growth in investment returns[6]. - The total non-recurring gains and losses for Q3 2023 amounted to ¥1,640,936.28, with government subsidies contributing significantly to this figure[4]. - Financial expenses for the period were CNY 57,742,257.87, slightly up from CNY 57,056,147.81 in the previous period[15]. - Deferred income decreased to CNY 66,597,240.88 from CNY 71,825,767.12, a decline of 7.2%[15]. - Total equity attributable to shareholders of the parent company was CNY 2,317,359,851.64, down from CNY 2,336,859,413.77, a decrease of 0.8%[15]. Audit and Accounting Standards - The company did not undergo an audit for the third quarter report, which was released on October 26, 2023[19]. - The company is implementing new accounting standards starting in 2023, which may affect financial reporting[19].